FDA Determines Regulatory Review Period for LUZU Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for LUZU, a human drug product, in accordance with U.S. law, following a submission to the U.S. Patent and Trademark Office (USPTO).